An amyloid PET scan typically costs $1,300 to $4,600 without insurance, with an average of around $3,000 per scan in freestanding imaging centers and $3,000 to $6,000 at hospital outpatient facilities. The actual amount you pay depends heavily on your insurance status, your specific facility, and where you live—but in 2026, there are more coverage options available than ever before. For a 72-year-old patient in Ohio with Medicare coverage, a scan at an independent imaging center might result in $283 for the Part B deductible plus 20% coinsurance on the CMS-approved amount, typically coming to around $550 total after Medicare covers its 80% share.
Medicare’s shift in October 2023 to eliminate the “one scan per lifetime” restriction and allow coverage outside of formal research studies has made amyloid PET more accessible, but it also introduced new complexity. Your out-of-pocket cost depends on whether you’re insured through Medicare, a private plan, or a Medicare Advantage product—and for Medicare beneficiaries specifically, whether you’re willing to enroll in a CMS-approved registry like the IDEAS study. Understanding the full picture of what these scans cost and what insurance will cover requires looking at several moving pieces.
Table of Contents
- What Does an Amyloid PET Scan Cost Without Insurance?
- Medicare Coverage and Out-of-Pocket Expenses for 2026
- Why Costs Vary: Facility Type, Location, and Overhead
- Navigating Prior Authorization and Insurance Approval
- New Medicare Requirements: The IDEAS Study and Registry Enrollment
- Private Insurance Coverage and Medicare Advantage Plans
- Understanding Radiotracer Costs and Physician Interpretation Fees
What Does an Amyloid PET Scan Cost Without Insurance?
For uninsured patients or those paying cash, amyloid pet scans range from $1,300 at the lower end to $4,600 at the higher end, with a typical cost of approximately $3,000. However, this average masks a significant difference based on facility type. A freestanding imaging center—often an independent diagnostic facility not owned by a hospital system—typically charges $1,500 to $2,800 for the same scan. A hospital outpatient department runs $3,000 to $6,000, with the higher end reflecting overhead costs for facility maintenance, equipment, and staffing that independent centers avoid. The radiotracer itself accounts for a substantial portion of the cost.
The three FDA-approved beta-amyloid tracers (Florbetapir, marketed as Amyvid; florbetaben, marketed as Vizamyl; and florbatesiren, marketed as Tauvid) each cost approximately $3,000 per dose. This expense is incurred once per patient visit—you receive one dose during your scan appointment—but it represents the largest single component of the bill. Physician interpretation fees and facility overhead add to this base cost. For a concrete example: a patient in a mid-sized city undergoing an amyloid PET scan at a hospital-owned outpatient imaging center without insurance might see a total bill of $5,200, while the same scan at a nearby independent imaging center could cost $2,100 for identical diagnostic value. That $3,100 difference reflects facility economics, not medical differences.
Medicare Coverage and Out-of-Pocket Expenses for 2026
medicare Part B covers amyloid PET scans, but beneficiaries face a deductible and coinsurance responsibility. In 2026, the Part B deductible is $283 per year. Once you meet this deductible, Medicare covers 80% of the approved amount, and you pay the remaining 20% as coinsurance. The CMS reimbursement rate for amyloid PET imaging ranges from $1,327.27 to $1,489.35 per scan, depending on specific technical factors and the facility type. This means a Medicare beneficiary might pay $283 for the annual deductible (if not yet met), plus 20% of roughly $1,400 in approved charges, equaling approximately $563 total out-of-pocket, with Medicare covering about $1,120.
However, this scenario assumes the scan is performed at a facility that accepts Medicare assignment. If your provider doesn’t accept assignment, you could face higher out-of-pocket costs, as they’re permitted to charge up to 15% above the Medicare-approved amount. A critical limitation: as of 2026, Medicare will only cover an amyloid PET scan if you enroll in the IDEAS study (Imaging Dementia—Evidence for Amyloid Scanning) or another CMS-approved registry. Scans performed outside this framework, even if you have Medicare, will be denied. This requirement was put in place to gather real-world evidence on how amyloid scanning affects patient outcomes and treatment decisions. If you obtain a scan without this enrollment, you become responsible for the full cost, regardless of your Medicare status.
Why Costs Vary: Facility Type, Location, and Overhead
The dramatic cost difference between hospital outpatient facilities ($3,000–$6,000) and freestanding centers ($1,500–$2,800) reflects differences in operational overhead rather than scan quality. Hospitals maintain broader infrastructure—emergency departments, surgical suites, inpatient beds, IT systems, compliance departments—that imaging doesn’t directly use but is required to support. Independent imaging centers focus narrowly on outpatient diagnostics and avoid these fixed costs. Geographic location also drives variation. An amyloid PET scan in a rural area of the upper Midwest may cost $2,200 at an independent facility, while an identical scan in a major metropolitan area like New York or Los Angeles could cost $3,500. This reflects differences in real estate costs, labor markets, and local healthcare pricing practices.
Medicare’s regional pricing system attempts to account for these differences through Medicare Administrative Contractors (MACs), who set local payment amounts. However, private insurance companies set their own rates independently, leading to further variation. A practical warning: even if your insurance covers the scan, the facility you choose matters significantly. Not all imaging centers are equivalent in terms of insurance participation. Some may accept Medicare but not your private insurance, or vice versa. Before scheduling, confirm that your chosen facility is in-network for your specific plan. An out-of-network scan at what seems like a lower-cost facility can result in much higher patient responsibility if your insurer pays less than billed charges.
Navigating Prior Authorization and Insurance Approval
Both Medicare and private insurance typically require prior authorization before an amyloid PET scan. For Medicare beneficiaries, this now means documented enrollment in the IDEAS study or a CMS-approved research registry—confirmation of this enrollment must be provided to the imaging center before your scan date. The process usually takes 2–4 weeks, so advance planning is essential. Private health insurance companies vary in their coverage policies. Most major insurers (United Healthcare, Aetna, Cigna, Anthem) cover amyloid PET scanning, but nearly all require prior authorization and medical documentation justifying the scan.
Your neurologist must demonstrate that you meet criteria—typically, cognitive decline or symptoms suggestive of Alzheimer’s disease, with a clinical need to assess amyloid burden to guide treatment decisions. Denial rates for insufficiently documented requests can range from 10% to 25%, depending on the insurer. If your insurance denies prior authorization, you have the right to appeal. Bring documentation of cognitive testing, imaging findings, or other diagnostic work supporting the medical necessity. Some patients successfully appeal initial denials by providing additional clinical evidence. However, this process adds 4–8 weeks to your timeline, so requesting authorization as early as possible—ideally before your neurologist suspects you need the scan, during the initial diagnostic workup—is important.
New Medicare Requirements: The IDEAS Study and Registry Enrollment
The IDEAS (Imaging Dementia—Evidence for Amyloid Scanning) study represents a significant shift in how Medicare covers amyloid PET. Launched as a condition for coverage, enrollment is now mandatory for Medicare beneficiaries seeking coverage. The study collects data on outcomes for patients who underwent amyloid scanning and allows CMS to monitor whether these scans improve clinical decision-making and patient outcomes. Enrollment is straightforward: your neurologist or primary care physician can register you in IDEAS or another CMS-approved registry before scheduling your scan. The process is free and non-invasive—it involves providing demographic information and consent to follow-up data collection.
However, it does add a step that wasn’t required before October 2023, and not all patients or clinicians are aware of this requirement. Missing enrollment can result in a full bill denial even if your neurologist believed Medicare would cover it. The specific registries approved as of 2026 include IDEAS, but others may be available depending on your region. Ask your imaging center which registries they work with, as they often handle enrollment coordination directly. If your preferred imaging center doesn’t work with any approved registry, you may need to switch facilities or manage the enrollment process yourself—a burden that could delay your scan by weeks.
Private Insurance Coverage and Medicare Advantage Plans
Private health insurance typically covers amyloid PET scans more straightforwardly than Medicare did historically. Most major insurers approved amyloid PET coverage several years ago, recognizing its clinical value in guiding Alzheimer’s disease treatment. However, coverage rates and out-of-pocket costs vary. A typical private plan might cover 80–90% of in-network facility charges after the deductible, leaving the patient responsible for the deductible (often $500–$2,000 annually) plus 10–20% coinsurance. Medicare Advantage plans (Part C) have significant flexibility in how they structure coverage.
Some offer the same 80% coverage as Original Medicare after meeting a deductible; others cover the scan at 90% or require higher copays. Prior authorization requirements are nearly universal. The critical limitation: coverage varies by specific plan and year, so calling your Medicare Advantage insurer directly to confirm coverage before scheduling is essential. Do not assume that because Original Medicare covers the scan, your Medicare Advantage plan will cover it identically. For a real-world example, a patient with a CIGNA Medicare Advantage plan might face a $250 copay for the scan and be responsible for any balance above the plan’s allowed amount if they choose an out-of-network facility. That same scan through Original Medicare would cost roughly 20% coinsurance on the approved amount, which might total $280—similar overall but with different cost structures.
Understanding Radiotracer Costs and Physician Interpretation Fees
The radiotracer represents the single largest cost component, at approximately $3,000 per dose. This reflects both the manufacturing complexity of beta-amyloid tracers and their short half-lives, which limit storage and transport. Florbetapir (Amyvid), the oldest approved tracer, has a half-life of 110 minutes. Florbetaben (Vizamyl) has a half-life of 20 minutes. Florbatesiren (Tauvid), the most recently approved, has a half-life of 32 minutes. The shorter the half-life, the closer production must be to the imaging facility, and the higher the cost per dose.
Physician interpretation fees are typically modest by comparison—ranging from $150 to $400 for the radiologist’s reading and report. However, if the radiologist needs to perform additional analysis or if the scan findings are complex, fees can reach $500–$800. For a Medicare-covered scan, the physician fee is bundled into the CMS reimbursement, so it doesn’t appear as a separate patient bill. Insurance companies sometimes try to reduce costs by limiting coverage to a single tracer. If your insurance approves only Vizamyl but your facility stocks Amyvid, you may need to choose between scheduling at a different facility, requesting the specific tracer your insurance covers, or paying the difference out of pocket. This nuance is rarely discussed upfront, but asking your imaging center which tracers are in-stock and whether your insurance has tracer-specific preferences can avoid last-minute cost surprises.
